PA8503201A1 - Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis - Google Patents

Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis

Info

Publication number
PA8503201A1
PA8503201A1 PA20008503201A PA8503201A PA8503201A1 PA 8503201 A1 PA8503201 A1 PA 8503201A1 PA 20008503201 A PA20008503201 A PA 20008503201A PA 8503201 A PA8503201 A PA 8503201A PA 8503201 A1 PA8503201 A1 PA 8503201A1
Authority
PA
Panama
Prior art keywords
ring
piridines
replaced
inhibition activity
piridacines
Prior art date
Application number
PA20008503201A
Other languages
English (en)
Spanish (es)
Inventor
Jaques P Dumas
Steoheb James Boyeer
Julie A Dixon
Teddy Kite Joe
Harold C E Kluender
Wendy Lee
Dhanapalan Nagrathnam
Robert N Sibley
Ning Su
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of PA8503201A1 publication Critical patent/PA8503201A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
PA20008503201A 1999-09-28 2000-09-25 Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis PA8503201A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40760099A 1999-09-28 1999-09-28

Publications (1)

Publication Number Publication Date
PA8503201A1 true PA8503201A1 (es) 2002-08-26

Family

ID=23612752

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20008503201A PA8503201A1 (es) 1999-09-28 2000-09-25 Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis

Country Status (35)

Country Link
EP (1) EP1228063B1 (en:Method)
JP (1) JP4919567B2 (en:Method)
KR (3) KR100895572B1 (en:Method)
CN (3) CN100422173C (en:Method)
AR (3) AR025752A1 (en:Method)
AT (1) ATE422494T1 (en:Method)
AU (1) AU782820B2 (en:Method)
BG (1) BG65860B1 (en:Method)
BR (1) BRPI0014382B8 (en:Method)
CA (1) CA2385817C (en:Method)
CO (1) CO5200835A1 (en:Method)
CZ (1) CZ304767B6 (en:Method)
DE (1) DE60041548D1 (en:Method)
DO (1) DOP2000000070A (en:Method)
EE (1) EE05258B1 (en:Method)
ES (1) ES2320525T3 (en:Method)
GT (1) GT200000158A (en:Method)
HR (1) HRP20020308A2 (en:Method)
HU (1) HU230223B1 (en:Method)
IL (3) IL148880A0 (en:Method)
MA (1) MA25563A1 (en:Method)
MX (1) MXPA02003156A (en:Method)
MY (3) MY143377A (en:Method)
NO (1) NO20021520L (en:Method)
NZ (1) NZ518589A (en:Method)
PA (1) PA8503201A1 (en:Method)
PE (1) PE20010607A1 (en:Method)
PL (1) PL205957B1 (en:Method)
RS (1) RS50369B (en:Method)
RU (1) RU2260008C2 (en:Method)
SK (1) SK287417B6 (en:Method)
TW (1) TW593315B (en:Method)
UA (1) UA75053C2 (en:Method)
WO (1) WO2001023375A2 (en:Method)
ZA (1) ZA200202760B (en:Method)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL154034A0 (en) * 2000-08-09 2003-07-31 Astrazeneca Ab Indole, azaindole and indazole derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals
RU2264389C3 (ru) 2000-10-20 2018-06-01 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Азотсодержащие ароматические производные, их применение, лекарственное средство на их основе и способ лечения
AU2002364102A1 (en) * 2001-12-21 2003-07-30 Bayer Pharmaceuticals Corporation Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
TWI299664B (en) 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds
PL1603566T3 (pl) * 2003-03-11 2009-07-31 Novartis Ag Zastosowanie pochodnych izochinoliny do leczenia raka i chorób związanych z kinezą MAP
US20070082910A1 (en) * 2003-04-08 2007-04-12 Mitsubishi Pharma Corporation Specific nad(p)h oxidase inhibitor
CN100450998C (zh) 2003-11-11 2009-01-14 卫材R&D管理有限公司 脲衍生物的制备方法
KR100553398B1 (ko) * 2004-03-12 2006-02-16 한미약품 주식회사 티에노[3,2-ｃ]피리딘 유도체의 제조 방법 및 이에사용되는 중간체
EP2364699A1 (en) 2004-09-13 2011-09-14 Eisai R&D Management Co., Ltd. Joint use of sulfonamide based compound with angiogenesis inhibitor
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
CN101001629B (zh) 2004-09-17 2010-05-05 卫材R&D管理有限公司 药物组合物
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
EP2010173A1 (en) * 2006-04-15 2009-01-07 Bayer HealthCare AG Compounds for treating pulmonary hypertension
CA2652442C (en) 2006-05-18 2014-12-09 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
EP2065372B1 (en) 2006-08-28 2012-11-28 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
CN101600694A (zh) 2007-01-29 2009-12-09 卫材R&D管理有限公司 未分化型胃癌治疗用组合物
CA2704000C (en) 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
CN101481380B (zh) * 2008-01-08 2012-10-17 浙江医药股份有限公司新昌制药厂 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途
BR112012032462A2 (pt) 2010-06-25 2016-11-08 Eisai R&D Man Co Ltd agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase.
US8962650B2 (en) 2011-04-18 2015-02-24 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
BR112015009004A8 (pt) 2012-12-21 2021-07-20 Eisai R&D Man Co Ltd forma amorfa de derivado de quinolina e método de produção da mesma
CA2912219C (en) 2013-05-14 2021-11-16 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN103396361B (zh) * 2013-07-24 2016-05-04 中国人民解放军第二军医大学 3,4-二氢异喹啉类抗肿瘤化合物及其制备方法与应用
JO3783B1 (ar) 2014-08-28 2021-01-31 Eisai R&D Man Co Ltd مشتق كوينولين عالي النقاء وطريقة لإنتاجه
BR112017017428A2 (pt) 2015-02-25 2018-04-03 Eisai R&D Management Co., Ltd. ?método para supressão do amargor de derivado de quinolina?
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
CN104804008B (zh) * 2015-03-27 2016-03-23 亿腾药业（泰州）有限公司 一种工业化生产甲磺酸特拉替尼的方法
KR102705821B1 (ko) 2015-06-16 2024-09-12 가부시키가이샤 프리즘 바이오랩 항암제
SG11201801083UA (en) 2015-08-20 2018-03-28 Eisai R&D Man Co Ltd Tumor therapeutic agent
BR112019014127A2 (pt) 2017-02-08 2020-02-11 Eisai R&D Management Co., Ltd. Composição farmacêutica para tratamento de tumores
CN107129502B (zh) * 2017-04-13 2022-08-05 泰州亿腾景昂药业股份有限公司 EOC315 Mod.I晶型化合物及其制备方法
WO2018212202A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
JP7624404B2 (ja) * 2019-04-22 2025-01-30 ミラティ セラピューティクス，インク． Ｐｒｃ２阻害剤としてのナフチリジン誘導体
CN112830932B (zh) * 2020-12-25 2022-04-08 泰州亿腾景昂药业股份有限公司 特拉替尼的游离碱晶型及其制备方法与用途
CA3237696A1 (en) 2021-11-08 2023-05-11 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1453897A (fr) * 1965-06-16 1966-07-22 Dérivés du thiophène et de thiéno pyridazines
GB1094044A (en) * 1965-07-12 1967-12-06 Vantorex Ltd Phthalazine derivatives
FR1516777A (fr) * 1966-08-02 1968-02-05 Innothera Lab Sa Dérivés du thiazole ainsi que de la thiazolo [4,5-d] pyridazine et leur préparation
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
JPH03106875A (ja) * 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd １―（３―ピリジルメチル）フタラジン誘導体
NZ290952A (en) * 1994-08-09 1998-05-27 Eisai Co Ltd Phthalazine derivatives optionally substituted in position-1 by (generally benzyl) amino groups
IL118631A (en) * 1995-06-27 2002-05-23 Tanabe Seiyaku Co History of pyridazinone and processes for their preparation
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
BR9912938B1 (pt) * 1998-08-11 2011-06-28 derivados de isoquinolina, composição que os compreende, processo para preparação e uso dos mesmos.
ES2265929T3 (es) * 1999-03-30 2007-03-01 Novartis Ag Derivados de ftalazina para el tratamiento de enfermedades inflamatorias.
AR025068A1 (es) * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
ES2241781T3 (es) * 2000-02-09 2005-11-01 Novartis Ag Derivados de piridina inhibidores de la angiogenesis y/o del receptor tirosina quinasa de vegf.

Also Published As

Publication number Publication date
MA25563A1 (fr) 2002-10-01
CO5200835A1 (es) 2002-09-27
CA2385817C (en) 2010-05-04
CN100422173C (zh) 2008-10-01
BR0014382B1 (pt) 2014-04-01
RS50369B (sr) 2009-11-10
HK1091818A1 (zh) 2007-01-26
EE05258B1 (et) 2010-02-15
ATE422494T1 (de) 2009-02-15
IL193368A0 (en) 2009-02-11
MY135058A (en) 2008-01-31
PL366342A1 (en) 2005-01-24
NZ518589A (en) 2005-03-24
AR082231A2 (es) 2012-11-21
SK287417B6 (sk) 2010-09-07
EE200200161A (et) 2003-08-15
CZ20021444A3 (cs) 2002-08-14
DE60041548D1 (de) 2009-03-26
AU1569601A (en) 2001-04-30
BG106637A (bg) 2003-02-28
KR100895572B1 (ko) 2009-04-29
KR100895571B1 (ko) 2009-04-29
IL148880A0 (en) 2002-09-12
CZ304767B6 (cs) 2014-10-08
WO2001023375A3 (en) 2002-05-02
IL193367A (en) 2011-03-31
KR20020038775A (ko) 2002-05-23
EP1228063B1 (en) 2009-02-11
HRP20020308B1 (en:Method) 2013-01-31
MY143580A (en) 2011-05-31
DOP2000000070A (es) 2002-02-28
JP2003526632A (ja) 2003-09-09
MXPA02003156A (es) 2002-09-30
CA2385817A1 (en) 2001-04-05
PE20010607A1 (es) 2001-07-12
RU2260008C2 (ru) 2005-09-10
ES2320525T3 (es) 2009-05-25
SK5912002A3 (en) 2003-01-09
MY143377A (en) 2011-05-13
JP4919567B2 (ja) 2012-04-18
PL205957B1 (pl) 2010-06-30
TW593315B (en) 2004-06-21
NO20021520L (no) 2002-05-23
CN1420879A (zh) 2003-05-28
NO20021520D0 (no) 2002-03-26
BG65860B1 (bg) 2010-03-31
AR082232A2 (es) 2012-11-21
HK1091819A1 (zh) 2007-01-26
AR025752A1 (es) 2002-12-11
UA75053C2 (en) 2006-03-15
HUP0202704A3 (en) 2003-12-29
BR0014382A (pt) 2003-06-24
CN1769282A (zh) 2006-05-10
EP1228063A2 (en) 2002-08-07
AU782820B2 (en) 2005-09-01
KR20080086547A (ko) 2008-09-25
KR100890473B1 (ko) 2009-03-26
IL193367A0 (en) 2009-02-11
ZA200202760B (en) 2003-10-29
HRP20020308A2 (en) 2004-06-30
YU22902A (sh) 2004-12-31
HU230223B1 (en) 2015-10-28
GT200000158A (es) 2002-03-16
CN100422172C (zh) 2008-10-01
BRPI0014382B8 (pt) 2021-05-25
WO2001023375A2 (en) 2001-04-05
HUP0202704A2 (hu) 2002-12-28
IL193368A (en) 2011-05-31
KR20080091505A (ko) 2008-10-13
CN1769283A (zh) 2006-05-10
CN100374435C (zh) 2008-03-12

Similar Documents

Publication Publication Date Title
PA8503201A1 (es) Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis
ES2100187T3 (es) Derivados de carboestirilos y composiciones farmaceuticas que los contienen.
HUP0003929A2 (hu) Piperazinszármazékok és alkalmazásuk gyulladásgátló hatású gyógyszerkészítmények előállítására, valamint a vegyületeket tartalmazó gyógyszerkészítmények
NO302570B1 (no) Substituerte pipekolinsyrederivater som HIV-protease-inhibitorer, farmasöytiske blandinger inneholdende dem og anvendelser av derivatene
ES2109647T3 (es) Fotoiniciadores funcionalizados, macromeros de estos y su empleo.
DE69133466D1 (de) Retrovirusprotease Inhibitoren
ES2053609T3 (es) Derivados de urea inhibidores de lipoxigenasa.
ES2132580T3 (es) Derivados de aroil-piperidina.
NO950550D0 (no) Sulfonylalkanoylamino-hydroksyetylaminosulfonamider som er nyttige som retrovirale proteaseinhibitorer
DE69635183D1 (de) Verbindungen der struktur bis-aminosäure-hydroxyethylamino-sulfonamid als inhibitoren der retroviralen protease
DK0625987T3 (da) Aminoacetylmercaptoacetylamid-derivater, der kan anvendes som inhibitorer af enkephalinase og ACE
ES2079576T3 (es) Derivados piranicos biciclicos y su uso como inhibidores de 5-lipoxigenasa.
NO921609L (no) Sulfonamider og deres medisinske anvendelse
ES2158109T3 (es) Nuevo derivado de indano fusionado y sal del mismo farmaceuticamente aceptable.
DK0885881T3 (da) Sulfonylalkanoylaminohydroxyethylaminosulfaminsyrer, der er anvendelige som retrovirale proteaseinhibitorer
DE69911935D1 (de) Granulatimide-derivate zur behandlung von krebs
DE69006220D1 (de) Ferrate von alkali- oder erdalkalimetallen, deren herstellung und deren industrielle verwendung.
BR9807447A (pt) Cobertura para objetos que entram em contato com artigos de vidro durante o seu processo de moldagem
BR9814188A (pt) "agonistas de 5-ht1f"
ES2071036T3 (es) Derivados de 6-o-metileritromicina a oxima.
ES2183940T3 (es) Inhibidores de proteasas de parasitos metazoarios.
ATE109139T1 (de) Mittel zum schutz von pflanzen gegen krankheiten.
DK0736009T3 (da) N-oxider af 4-arylpiperaziner og 4-arylpiperidiner som antipsykotiske medikamenter
AR004484A1 (es) Nuevas 1,2,3,4-tetrahidro-2-naftalenaminas fenilo-sustituidas en el anillo aromatico, su preparacion, sus aplicaciones terapeuticas y las composicionesfarmaceuticas que las contienen.
UY34282A (es) Piridacinas sustituidas con actividad de inhibición de angiogénesis